Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Technology services tags : Cancer save search
BostonGene and Saga University Announce Collaboration to Uncover Biomarkers for Improved Immunotherapy Response in Lung Cancer Patients
Published: 2024-04-16 (Crawled : 13:00) - biospace.com/
NIPNF | $68.91 -52.94% 120
|
Technology Services
| Email alert
Add to watchlist
lung cancer immunotherapy for collaboration saga response biomarkers
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
NIPNF | $68.91 -52.94% 120
|
Technology Services
| Email alert
Add to watchlist
tg4050 first cancer benefits
iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
ICAD | $1.57 0.64% 0.64% 140K
|
Technology Services
|
| O: 5.7%
H: 11.98%
C: 7.78%
precision breast health cancer risk solutions for
iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
ICAD | $1.57 0.64% 0.64% 140K
|
Technology Services
|
| O: 1.25%
H: 18.52%
C: 17.28%
breast cancer
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Published: 2024-03-05 (Crawled : 07:00) - globenewswire.com
NIPNF | $68.91 -52.94% 120
|
Technology Services
| Email alert
Add to watchlist
tg4050 vaccine cancer collaboration trial
iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
Published: 2024-02-28 (Crawled : 13:00) - globenewswire.com
ICAD | $1.57 0.64% 0.64% 140K
|
Technology Services
|
| O: -0.64%
H: 22.76%
C: 12.82%
breast cancer platform
Cancer Clinical Decision Tools Market Poised for Robust Growth: Comprehensive Analysis Revealed in New Global Report
Published: 2024-02-13 (Crawled : 04:00) - prnewswire.com
MCK | $518.81 -1.35% 0.0% 630K
|
Distribution Services
|
| O: 0.31%
H: 2.22%
C: 1.77%
PHG | $19.98 -0.84% 0.0% 500K
|
Health Technology
|
| O: -2.76%
H: 0.45%
C: -0.2%
ARAY | $2.21 0.91% 0.9% 690K
|
Health Technology
|
| O: -3.91%
H: 6.67%
C: 1.85%
report cancer tools global market
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Published: 2024-01-08 (Crawled : 17:00) - globenewswire.com
NIPNF | $68.91 -52.94% 120
|
Technology Services
| Email alert
Add to watchlist
tg4050 vaccine cancer collaboration
7 Ways Health Plans Can Improve Quality in Cancer Care
Published: 2023-12-12 (Crawled : 15:30) - nanthealth.com
NHIQ | $0.341 16.76% 110
|
Information
|
| O: 66.48%
H: 0.0%
C: -14.19%
health cancer care
7 Ways Health Plans Can Improve Poor Quality in Cancer Care
Published: 2023-12-12 (Crawled : 22:00) - nanthealth.com
NHIQ | $0.341 16.76% 110
|
Information
|
| O: 66.48%
H: 0.0%
C: -14.19%
health cancer care
Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen Inc., Arrien Pharmaceuticals LLC and more among the key companies in the market - Technavio
Published: 2023-12-05 (Crawled : 23:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.64%
H: 0.0%
C: -1.33%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 1.51%
H: 0.13%
C: -1.68%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.52%
H: 0.18%
C: -0.43%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.03%
H: 0.28%
C: -0.41%
BAX | $39.65 0.33% 0.0% 2.3M
|
Health Technology
|
| O: 0.14%
H: 0.78%
C: 0.22%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.73%
H: 0.06%
C: -1.38%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.2%
H: 0.2%
C: -0.76%
GOOGL | News S | $155.97 0.32% 0.32% 19M
|
Technology Services
|
| O: 1.97%
H: 0.0%
C: 0.0%
GOOG | News S | $157.49 0.39% 0.39% 14M
|
Technology Services
|
| O: 1.97%
H: 0.0%
C: 0.0%
ADBE M | $472.91 -0.33% -0.33% 2.4M
|
Technology Services
|
| O: 0.97%
H: 0.08%
C: -2.03%
tube companies abbvie cancer pharmaceuticals therapeutics market
iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare
Published: 2023-11-28 (Crawled : 13:00) - globenewswire.com
ICAD | $1.57 0.64% 0.64% 140K
|
Technology Services
|
| O: 8.76%
H: 12.75%
C: 5.37%
breast cancer solutions collaboration
iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease
Published: 2023-11-27 (Crawled : 13:00) - globenewswire.com
ICAD | $1.57 0.64% 0.64% 140K
|
Technology Services
|
| O: 0.75%
H: 7.41%
C: 1.48%
reveal disease breast year cancer risk heart
5 Cancer Vaccines to Watch in 2024
Published: 2023-11-20 (Crawled : 06:00) - biospace.com/
NIPNF | $68.91 -52.94% 120
|
Technology Services
| Email alert
Add to watchlist
cancer
Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
XAIR | $1.175 -8.2% -8.94% 610K
|
Technology Services
|
| O: 2.03%
H: 3.98%
C: -8.76%
beyond tumors positive cancer immunotherapy meeting therapy
Liquid Biopsy Market size is set to grow by USD 1.74 billion from 2021 to 2026 | The Increasing incidence of cancer drives the market growth - Technavio
Published: 2023-10-24 (Crawled : 08:00) - prnewswire.com
ANPCY | $1.98 338.38% 930
|
Manufacturing
|
| O: 24.59%
H: 0.0%
C: 0.0%
ACN | $316.0 0.46% 0.0% 3M
|
Technology Services
|
| O: 0.45%
H: 0.58%
C: -0.06%
TECH | $62.25 -0.77% -0.77% 1.2M
|
Health Technology
|
| O: -0.14%
H: 1.15%
C: 0.49%
cancer set growth market
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Published: 2023-10-16 (Crawled : 12:00) - globenewswire.com
XAIR | $1.175 -8.2% -8.94% 610K
|
Technology Services
|
| O: 2.68%
H: 0.43%
C: -2.61%
conference beyond positive cancer international preclinical therapeutics therapy molecular
Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Published: 2023-10-04 (Crawled : 12:00) - globenewswire.com
XAIR | $1.175 -8.2% -8.94% 610K
|
Technology Services
|
| O: 0.95%
H: 3.76%
C: 0.94%
conference beyond cancer international program therapeutics therapy molecular
BostonGene and Hokkaido University Hospital Collaborate to Develop Novel HER2 Protocols for Breast Cancer
Published: 2023-09-19 (Crawled : 14:30) - biospace.com/
NIPNF | $68.91 -52.94% 120
|
Technology Services
| Email alert
Add to watchlist
breast her2 hospital cancer
CAR T-cell Therapy: Genetically Modifying the Immune System to Attack Blood Cancer and Clinical Applications in Nursing Practice
Published: 2023-08-23 (Crawled : 13:30) - nanthealth.com
NHIQ | $0.341 16.76% 110
|
Information
|
| O: -2.5%
H: 0.0%
C: 0.0%
t-cell cancer blood system
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.